Pillstats
Injection, Solution

Galcanezumab-Gnlm

Galcanezumab

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCN02CD02
RxCUI (US)2058846
US makers1 labelers
Packages4
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$193.64$387.27$580.91$774.54Dec 2025May 2026Jul 2026
$673.278
Latest avg · Jul 22, 2026
+3%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

5.0K10K15K20K2025 Q12025 Q22025 Q32025 Q42026 Q1
15K
Rx · 2026 Q1
21K
Units dispensed
-8%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Eli Lilly and Companyunknown4SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.